CR20240371A - Vacunas terapéuticas anti-alfa-sinucleína - Google Patents
Vacunas terapéuticas anti-alfa-sinucleínaInfo
- Publication number
- CR20240371A CR20240371A CR20240371A CR20240371A CR20240371A CR 20240371 A CR20240371 A CR 20240371A CR 20240371 A CR20240371 A CR 20240371A CR 20240371 A CR20240371 A CR 20240371A CR 20240371 A CR20240371 A CR 20240371A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sub
- present
- defined above
- peptide antigen
- synuclein
- Prior art date
Links
- 229940021747 therapeutic vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 abstract 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22156007 | 2022-02-09 | ||
| EP22156006 | 2022-02-09 | ||
| PCT/EP2023/053259 WO2023152260A1 (en) | 2022-02-09 | 2023-02-09 | Anti-alpha-synuclein therapeutic vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240371A true CR20240371A (es) | 2024-10-16 |
Family
ID=85175955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240371A CR20240371A (es) | 2022-02-09 | 2023-02-09 | Vacunas terapéuticas anti-alfa-sinucleína |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250152684A1 (enExample) |
| EP (1) | EP4475878A1 (enExample) |
| JP (1) | JP2025506472A (enExample) |
| KR (1) | KR20240147981A (enExample) |
| AU (1) | AU2023219059A1 (enExample) |
| CA (1) | CA3248093A1 (enExample) |
| CL (1) | CL2024002370A1 (enExample) |
| CR (1) | CR20240371A (enExample) |
| IL (1) | IL314865A (enExample) |
| MX (1) | MX2024009485A (enExample) |
| WO (1) | WO2023152260A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024211543A1 (en) * | 2023-01-26 | 2025-07-17 | Ac Immune Sa | Liposomal construct |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| EP2659907A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| US12156912B2 (en) * | 2012-05-18 | 2024-12-03 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| RU2734924C2 (ru) | 2015-11-03 | 2020-10-26 | Аффирис Аг | Способ вакцинации против аутоантигена у пациента-человека |
| CN111787942B (zh) * | 2017-10-25 | 2024-03-29 | 杨森制药公司 | 磷酸化Tau肽的组合物及其用途 |
| AU2019253193B2 (en) * | 2018-04-10 | 2026-02-05 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
| CA3185563A1 (en) * | 2020-08-04 | 2022-02-10 | Dorian WINTER | Immunogenic compounds |
-
2023
- 2023-02-09 KR KR1020247025028A patent/KR20240147981A/ko active Pending
- 2023-02-09 MX MX2024009485A patent/MX2024009485A/es unknown
- 2023-02-09 JP JP2024547294A patent/JP2025506472A/ja active Pending
- 2023-02-09 CA CA3248093A patent/CA3248093A1/en active Pending
- 2023-02-09 US US18/836,298 patent/US20250152684A1/en active Pending
- 2023-02-09 WO PCT/EP2023/053259 patent/WO2023152260A1/en not_active Ceased
- 2023-02-09 AU AU2023219059A patent/AU2023219059A1/en active Pending
- 2023-02-09 CR CR20240371A patent/CR20240371A/es unknown
- 2023-02-09 IL IL314865A patent/IL314865A/en unknown
- 2023-02-09 EP EP23703593.6A patent/EP4475878A1/en active Pending
-
2024
- 2024-08-07 CL CL2024002370A patent/CL2024002370A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023152260A1 (en) | 2023-08-17 |
| AU2023219059A1 (en) | 2024-07-25 |
| JP2025506472A (ja) | 2025-03-11 |
| MX2024009485A (es) | 2024-08-14 |
| CA3248093A1 (en) | 2023-08-17 |
| US20250152684A1 (en) | 2025-05-15 |
| CL2024002370A1 (es) | 2024-12-27 |
| KR20240147981A (ko) | 2024-10-10 |
| IL314865A (en) | 2024-10-01 |
| EP4475878A1 (en) | 2024-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20240371A (es) | Vacunas terapéuticas anti-alfa-sinucleína | |
| IL152625A (en) | Synthetic but not amyloidogenic immunogenic peptides equivalent to amyloid b to elicit an immune response to amyloid b and amyloid deposits | |
| CA2489227A1 (en) | Hla-a24-restricted cancer antigen peptides | |
| BR9306820A (pt) | Conjugado de um antígeno fracamente imunogênico e um veículo peptideo sintetico vacina processos para melhorar a imunogenicidade de uma molecula de antigeno fracamente imunogenico e para imunizar um hospedeiro mamífero | |
| EP1619202A3 (en) | immunotherapeutic methods using epitopes of wt-1 and gata-1 | |
| NZ551802A (en) | A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof | |
| DK1531791T3 (da) | Forebyggelse og begrænsning af iskæmi | |
| MXPA04000597A (es) | Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna. | |
| WO2022119871A3 (en) | Novel compositions with tissue-specific targeting motifs and compositions containing same | |
| CA2242878A1 (en) | Induction of immune response against desired determinants | |
| MX2023001483A (es) | Compuestos inmunogenicos. | |
| MX2021014497A (es) | Peptidos. | |
| WO2003084568A3 (de) | Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung | |
| MX2022014649A (es) | Coctel de peptidos. | |
| DK193589A (da) | Hidtil ukendt polypeptid og fremgangsmaade til dets fremstilling | |
| MXPA06014393A (es) | Peptidos oligomericos y su uso para el tratamiento de infecciones por vih. | |
| WO2001027136A3 (fr) | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire | |
| NZ592340A (en) | A method for making a virus vaccine compising Replikin peptides | |
| US20200399311A1 (en) | Novel peptide based pcsk9 vaccine | |
| PE20010237A1 (es) | GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS OmpH, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS | |
| PE20010238A1 (es) | GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS SodC, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS | |
| MX2025008523A (es) | Construccion liposomal | |
| AU2003303218A1 (en) | Peptides and their use for the treatment of hiv infections | |
| WO2024052542A3 (en) | A peptide cocktail | |
| CA2446390A1 (en) | Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof |